BrainCheck Secures $13M Series A Financing

Why It Matters

The capital infusion enables BrainCheck to scale its clinically validated tools, strengthening its position in the rapidly growing digital cognitive‑health market.

Key Takeaways

• BrainCheck raised $13M Series A led by Next Coast Ventures
• Platform includes FDA Class II BrainCheck Assess digital test
• Over 500 healthcare organizations now use BrainCheck
• More than 640,000 assessments and 14,000 care plans completed
• Adoption spans 46 research hospitals, including UT Austin and Stanford

Pulse Analysis

The $13 million Series A round places BrainCheck among the fastest‑growing digital‑health startups attracting venture capital in 2024. Led by Next Coast Ventures, the financing follows a broader investor shift toward remote diagnostics, where scalable software can replace time‑intensive in‑person testing. Participation from S3 Ventures and UPMC Enterprises not only adds capital but also strategic clinical expertise, giving BrainCheck a foothold in both private and academic health systems. This infusion is expected to fund product enhancements, regulatory expansion, and sales acceleration across the United States.

BrainCheck’s flagship BrainCheck Assess™ is an FDA Class II digital cognitive assessment, a rare regulatory clearance that differentiates it from many wellness‑focused tools. The platform’s ability to generate standardized, repeatable data makes it attractive for both clinical pathways and research protocols. With more than 500 healthcare organizations and 46 research hospitals already integrated, the system has delivered over 640,000 assessments and 14,000 individualized care plans. These metrics demonstrate not only clinical adoption but also the scalability needed to support large‑scale population health initiatives.

The new funding positions BrainCheck to expand beyond its current U.S. footprint, targeting tele‑health networks and payer partnerships that value objective cognitive metrics. As the prevalence of dementia and age‑related cognitive decline rises, insurers are seeking cost‑effective screening solutions that can be deployed at scale. BrainCheck’s data‑rich platform also offers research institutions a robust tool for longitudinal studies, potentially accelerating drug development pipelines. If the company capitalizes on these trends, it could become a cornerstone of digital neurology, reshaping how clinicians diagnose and monitor cognitive health.